These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8003185)

  • 41. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
    J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-activity relationship studies of novel pyrazolo[1,5-c][1,3]benzoxazines: synthesis and benzodiazepine receptor affinity.
    Varano F; Catarzi D; Colotta V; Cecchi L; Filacchioni G; Galli A; Costagli C
    Arch Pharm (Weinheim); 1996 Dec; 329(12):529-34. PubMed ID: 9038420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postnatal development and kinetics of [3H]gaboxadol binding in rat brain: in vitro homogenate binding and quantitative autoradiography.
    Friemel A; Ebert B; Hutson PH; Brust P; Nieber K; Deuther-Conrad W
    Brain Res; 2007 Sep; 1170():39-47. PubMed ID: 17692833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor.
    Primofiore G; Da Settimo F; Taliani S; Simorini F; Patrizi MP; Novellino E; Greco G; Abignente E; Costa B; Chelli B; Martini C
    J Med Chem; 2004 Mar; 47(7):1852-5. PubMed ID: 15027878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Covalent modification of GABAA receptor isoforms by a diazepam analogue provides evidence for a novel benzodiazepine binding site that prevents modulation by these drugs.
    Baur R; Tan KR; Lüscher BP; Gonthier A; Goeldner M; Sigel E
    J Neurochem; 2008 Sep; 106(6):2353-63. PubMed ID: 18643789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Lenzi O; Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Varani K; Marighetti F; Morizzo E; Moro S
    J Med Chem; 2006 Jun; 49(13):3916-25. PubMed ID: 16789747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-activity relationships of 1,2,4-triazolo[1,5-a] quinoxalines and their 1-deaza analogues imidazo[1,2-a]quinoxalines at the benzodiazepine receptor.
    Catarzi D; Cecchi L; Colotta V; Melani F; Filacchioni G; Martini C; Giusti L; Lucacchini A
    J Med Chem; 1994 Sep; 37(18):2846-50. PubMed ID: 8071933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget.
    Fensome A; Bender R; Chopra R; Cohen J; Collins MA; Hudak V; Malakian K; Lockhead S; Olland A; Svenson K; Terefenko EA; Unwalla RJ; Wilhelm JM; Wolfrom S; Zhu Y; Zhang Z; Zhang P; Winneker RC; Wrobel J
    J Med Chem; 2005 Aug; 48(16):5092-5. PubMed ID: 16078826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 1,2,3-triazolo[1.5-a]quinazolines: synthesis, benzodiazepine receptor binding and theoretical calculations.
    Biagi G; Giorgi I; Livi O; Scartoni V; Velo S; Lucacchini A; Senatore G; De Santis B; Martinelli A
    Farmaco; 1996 Feb; 51(2):131-6. PubMed ID: 8857209
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
    Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
    J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of the stable conformation of GABA(A)-benzodiazepine receptor bivalent ligands by low temperature NMR and X-ray analysis.
    Han D; Försterling FH; Li X; Deschamps JR; Cao H; Cook JM
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1465-9. PubMed ID: 15006383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Studies on specific inhibition of benzodiazepine receptor binding by some C-benzoyl-1,2,3-triazole derivatives.
    Biagi G; Giorgi I; Livi O; Lucacchini A; Martini C; Scartoni V
    J Pharm Sci; 1993 Sep; 82(9):893-6. PubMed ID: 8229686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and benzodiazepine receptor affinity of N-(indol-3-ylglyoxylyl)-dipeptide derivatives. Structural requirements for inverse agonist/antagonist receptor interactions.
    Da Settimo A; Primofiore G; Da Settimo F; Bianucci A; Martini C; Senatore G; Lucacchini A
    Drug Des Discov; 1993; 10(3):199-211. PubMed ID: 8268392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Geometrically constrained analogues of N-benzylindolylglyoxylylamides: [1, 2, 4]triazino[4, 3-a]benzimidazol-4(10H)-one derivatives as potential new ligands at the benzodiazepine receptor.
    Primofiore G; Da Settimo F; Taliani S; Marini AM; Simorini F; Novellino E; Greco G; Trincavelli L; Martini C
    Arch Pharm (Weinheim); 2003 Sep; 336(9):413-21. PubMed ID: 14528489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benzodiazepine receptor ligands. III. Synthesis and biological evaluation of 2- and/or 3-substituted pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxides.
    Guerrini G; Costanzo A; Bruni F; Ciciani G; Selleri S; Gratteri P; Costa B; Martini C; Lucacchini A
    Farmaco; 1999 Jun; 54(6):375-89. PubMed ID: 10576777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.
    Hasui T; Matsunaga N; Ora T; Ohyabu N; Nishigaki N; Imura Y; Igata Y; Matsui H; Motoyaji T; Tanaka T; Habuka N; Sogabe S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
    J Med Chem; 2011 Dec; 54(24):8616-31. PubMed ID: 22074142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tricyclic heteroaromatic systems: synthesis, [3H]flunitrazepam brain membrane binding inhibition, and structure-activity relationships of 2,3-dihydro-2-aryl-4-R-[1]benzopyrano[4,3-c]pyrazole-3-ones.
    Colotta V; Cecchi L; Melani F; Palazzino G; Filacchioni G; Martini C; Giannaccini G; Lucacchini A
    J Pharm Sci; 1989 Mar; 78(3):239-42. PubMed ID: 2542524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specific inhibition of benzodiazepine receptor binding by some 1,2,3-triazole derivatives.
    Martini C; Marrucci W; Lucacchini A; Biagi G; Livi O
    J Pharm Sci; 1988 Nov; 77(11):977-80. PubMed ID: 2852246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pyrazolo [4,3-c] quinolines synthesis and specific inhibition of benzodiazepine receptor binding (Note I).
    Savini L; Massarelli P; Pellerano C; Fiorini I; Bruni G; Romeo MR
    Farmaco; 1993 Jan; 48(1):65-76. PubMed ID: 8384455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.